BCTX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (7 May 2024 @ 14:31):

Stats
Today's Volume	12 127.00
Average Volume	75 652.00
Market Cap	35.33M
EPS	$0 ( 2024-03-20 )
Next earnings date	( $-0.200 ) 2024-06-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.80
ATR14	$0.0260 (1.18%)

Insider Trading

Date	Person	Action	Amount	type
2022-12-28	Bondarenko Jamieson	Buy	28 000	Common Shares
2022-12-23	Williams William V.	Buy	2 530	Warrant
2022-12-20	Bondarenko Jamieson	Buy	22 000	Common Shares
2022-08-01	Bondarenko Jamieson	Sell	0	Common Shares
2021-03-29	Bondarenko Jamieson	Sell	150 000	Option (Right to Buy)

INSIDER POWER
-67.26
Last 25 transactions
Buy: 52 530 \| Sell: 1 209 572

Volume Correlation

Long: 0.03 (neutral)

Short: 0.13 (neutral)

Signal:(43.254) Neutral

BriaCell Therapeutics Correlation

10 Most Positive Correlations
EBTC	0.957
RDUS	0.953
PACB	0.943
BMRC	0.941
FLGT	0.941
RRBI	0.94
APPS	0.938
CLNE	0.938
RIVN	0.937
BPRN	0.937

10 Most Negative Correlations
ACGL	-0.94
GXII	-0.935
THAC	-0.929
TCDA	-0.925
VPCB	-0.92
AEAC	-0.92
RAM	-0.92
CPAA	-0.919
SVFB	-0.918
FAAR	-0.918

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

BriaCell Therapeutics Correlation - Currency/Commodity

0.05
( neutral )

0.07
( neutral )

0.00
( neutral )

0.27
( neutral )

0.08
( neutral )

0.04
( neutral )

BriaCell Therapeutics Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-15 529.00 (0.00 %)
EPS:	$-1.300

FY	2023
Revenue:	$0
Gross Profit:	$-15 529.00 (0.00 %)
EPS:	$-1.300

FY	2022
Revenue:	$0
Gross Profit:	$-15 141.00 (0.00 %)
EPS:	$-0.750

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.0900

Financial Reports:

No articles found.

BriaCell Therapeutics

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.